Pandemic Timeline

Patents

Moderna files patent US9828416: Modified polynucleotides for the production of secreted proteins

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

— Patent US9828416B2

A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, N1-methyl-pseudouridine, a 3′-UTR, and a poly-A region with at least 100 nucleotides.

⋮

In one embodiment, therapeutic nanoparticle may be formulated for sustained release. As used herein, “sustained release” refers to a pharmaceutical composition or compound that conforms to a release rate over a specific period of time. The period of time may include, but is not limited to, hours, days, weeks, months and years.  [page 120]

⋮

Disclosed nanoparticles can be used for a variety of applications, such as, without limitation, drug delivery, gene therapy, medical diagnosis, and for medical therapeutics for cancer, pathogen-borne diseases, hormone-related diseases, reaction-by-products associated with organ transplants, and other abnormal cell or tissue growth.  [section 0046]

⋮

Disclosed nanoparticles may include optional targeting moieties, which may be selected to ensure that the nanoparticles selectively attach to, or otherwise associate with, a selected marker or target. For example, in some embodiments, disclosed nanoparticles may be functionalized with an amount of targeting moiety effective for the treatment of prostate cancer in a subject (e.g., a low-molecular weight PSMA ligand). Through functionalization of nanoparticle surfaces with such targeting moieties, the nanoparticles are effective only at targeted sites, which minimizes adverse side effects and improves efficacy. Targeted delivery also allows for the administration of a lower dose of therapeutic agent, which may reduce undesirable side effects commonly associated with traditional treatments of disease.  [section 0074]

— Patent US10703789B2

This means they have built in targeted delivery and are delivering these nanoparticles intentionally to specific organs which would mean that what is referred to as “adverse events” may not be adverse at all but rather intentional based on the design of the encapsulated nanoparticles.

— Karen Kingston via Knowing The Truth

 

“Keep in mind, the Pfizer injection – all the mRNA products – fall under Moderna. So, it’s US Patent #10703789B2, issued on July 7th, 2020 and what you’ll see, right there is a description of the four lipid nanoparticles that are in here and that encapsulate the mRNA.”

— Karen Kingston on

Sources:

See also, on this site:

 

 

 

 

 

 

 

Comments are closed.